Insulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Insulet (PODD) Misses Q3 EPS by 2c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
November 5, 2019 4:33 PM ESTInsulet (NASDAQ: PODD) reported Q3 EPS of $0.01, $0.02 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $192.1 million versus the consensus estimate of $179.49 million.
Third Quarter Financial Highlights:
Third quarter revenue of $192.1 million, up 27%, compared to revenue of $151.1 million in the prior year, exceeds guidance of $174 to $181 millionGlobal Omnipod revenue of $177.2 million, an increase of 34%U.S. Omnipod revenue of $109.5 million, an increase of 34%International Omnipod revenue of $67.7 million, an increase of 35%Drug Delivery revenue of $14.9 million, a decrease of 21%Gross margin of... More